New hope for advanced cancers? JAB-8263 enters human testing

NCT ID NCT04686682

Recruiting now Disease control Sponsor: Jacobio Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called JAB-8263 in adults with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 152 people will take part in this early-phase trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia cancer esophageal squamous cell carcinoma mycosis fungoides neoplasm non-small cell lung carcinoma ovarian cancer ovarian carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML CRPC ESCC MALIGNANT TUMOR MF NSCLC OVARIAN CARCINOMA SCLC

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Tianjin
RECRUITING

Tianjin, Tianjin Municipality, 300020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.